Sulfonylureas and related compounds and use of same

The compound of any one of the preceding claims wherein R2 is selected from:

• wherein, each incidence of Y is independently selected from C, N, S and O, which may be optionally substituted as appropriate;
• R5, R11, R12, R13, R14 and R15 are independently selected from the group consisting of hydrogen, halo, cyano, amide, sulphonamide, acyl, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C3-C5 cyloalkyl, C1-C6 alkoxy all of which groups may be optionally substituted, as appropriate, with halo, cyano or C1-C6 alkoxy;
• and
• wherein R11 and R12 may combine to form phenyl, a 5- or 6-membered oxygen heterocycle or a 5- or 6-membered nitrogen heteroaryl, each of which may be optionally substituted;
• R12 and R13 may combine to form a 5- or 6-membered nitrogen heteroaryl, which may be optionally substituted;
• and
• R14 and R15 may combine to form a 5- or 6-membered cycloalkyl ring, phenyl, a 5- or 6-membered oxygen heterocycle or a 5- or 6-membered nitrogen heteroaryl, each of which may be optionally substituted.

The compound of any one of the preceding claims wherein the compound is a compound of formula (II), or a pharmaceutically acceptable salt, solvate or prodrug thereof:

• wherein, A, B, D and E are independently selected from C, N, O, S and Se, but at least one thereof is C;
• each dashed line may represent a bond
• R2 is as defined in any one of the preceding claims or R2 may be a fluorescent group;
• each incidence of R6 is independently selected from the group consisting of hydrogen, halide, cyano, C1-C6 alkyl, C1-C6 alkylamino, C1-C6 alkylhydroxy, C3-C6 cycloalkyl, alkylphenyl, phenyl, benzyl, C1-C6 ester, C2-C6 alkenyl, C1-C6 trifluoroalkyl and C1-C6 alkoxy, each of which may be optionally substituted, as appropriate, or R6 may be a fluorescent group.

The compound of any one of the preceding claims wherein the compound is a compound of formula (IIIa), (IIIb) or (IIIc), or a pharmaceutically acceptable salt, solvate or prodrug thereof:

• wherein, R21 is selected from H, alkyl, perhaloalkyl or hydroxylalkyl;
• R22 is selected from H, alkyl, perhaloalkyl, C3-C6 cycloalkyl, phenyl or benzyl;
• R18 is H or halogen;
• R16 and R17 are H, alkyl or cycloalkyl;
• or R16 and R17, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;
• R19 and R20 are H or alkyl;
• or R19 and R20, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;
• provided that R21 and R22 are not both H;
• and
• provided that R16, R17, R18, R19 and R20 are not all H.

The compound of any one of the preceding claims wherein the compound is a compound of formula (IVa), (IVb) or (IVc), or a pharmaceutically acceptable salt, solvate or prodrug thereof:

• wherein, R21 and R22 are selected from H, alkyl, perhaloalkyl, hydroxylalkyl, C3-C6 cycloalkyl, phenyl and benzyl or R21 and R22, together with the carbon atoms to which they are attached, may form a cyclopentyl or a cyclohexyl ring;
• R18 is H or halogen;
• R16 and R17 are H, alkyl or cycloalkyl;
• or R16 and R17, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;
• R19 and R20 are H or alkyl;
• or R19 and R20, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;
• provided that R21 and R22 are not both H;
• and
• provided that R16, R17, R18, R19 and R20 are not all H.

The compound of any one of the preceding claims wherein the compound is a compound of formula (Va), (Vb) or (Vc), or a pharmaceutically acceptable salt, solvate or prodrug thereof:

• wherein, R21 and R22 are selected from H, alkyl, perhaloalkyl, hydroxylalkyl, C3-C6 cycloalkyl, phenyl and benzyl;
• R18 is H or halogen;
• R16 and R17 are H, alkyl or cycloalkyl;
• or R16 and R17, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;
• R19 and R20 are H or alkyl;
• or R19 and R20, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;
• provided that R21 and R22 are not both H;
• and
• provided that R16, R17, R18, R19 and R20 are not all H.

The compound of any one of the preceding claims wherein the compound is a compound of formula (VIa) or (VIb), or a pharmaceutically acceptable salt, solvate or prodrug thereof:

• wherein, R22 is selected from alkyl, perhaloalkyl, hydroxylalkyl, C3-C6 cycloalkyl, phenyl and benzyl;
• R18 is H or halogen;
• R16 and R17 are H, alkyl or cycloalkyl;
• or R16 and R17, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;
• R19 and R20 are H or alkyl;
• or R19 and R20, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;
• and
• provided that R16, R17, R18, R19 and R20 are not all H.

The compound of any one of the preceding claims wherein the compound is a compound of formula (VII), or a pharmaceutically acceptable salt, solvate or prodrug thereof:

• wherein, Q is O or S;
• each incidence of R30 is independently selected from alkyl, perhaloalkyl, hydroxylalkyl, C3-C6 cycloalkyl, and alkylamino;
• R18 is H or halogen;
• R16 and R17 are H or alkyl;
• or R16 and R17, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;
• R19 and R20 are H or alkyl;
• or R19 and R20, together with the carbon atoms to which they are attached, form a 5 or 6 membered ring, said ring being saturated, partially unsaturated or unsaturated, said ring optionally comprising one or two heteroatoms selected from N, O and S;
• provided that R16, R17, R18, R19 and R20 are not all H;
• and
• provided that when Q is O and R16 and R17, and separately R19 and R20, together with the respective carbon atoms to which they are attached, form a cyclopentyl ring then R30 is not C-3 hydroxylalkyl.